EDITORIAL: BioCrossroads an example of vision at work
We hate to think what Indiana’s economic future might be if no one had made a point of putting the state’s life sciences assets to work in a coordinated, strategic way.
We hate to think what Indiana’s economic future might be if no one had made a point of putting the state’s life sciences assets to work in a coordinated, strategic way.
In the 10 years BioCrossroads has been promoting life sciences in Indiana, the effort has netted more than 330 new companies, an infusion of more than $330 million in venture capital, a tripling of exports, and a growing number of mentions in national reports on life sciences.
Indiana companies landed just $14.1 million in venture funding last year, the lowest amount of capital flowing to the state’s health care sector since BioEnterprises began tracking such deals in 2005.
The Indianapolis-based unit of Dow Chemical Co. saw earnings grow to $142 million, a fourth-quarter record and double the $72 million reported for the 2010 period.
Patent expirations on Gemzar and Zyprexa contributed to the 27-percent earnings decline, but CEO John Lechleiter touted better-than-expected sales of other products.
Purdue University’s new Innovation and Commercialization Center is supposed to be a one-stop shop for professors to get help developing their research into products and for outside investors to find out what research is taking place there.
Drugmaker Eli Lilly and Co.'s Elanco animal health division plans to buy a privately held maker of feed-enzyme products that improve poultry, egg and meat production.
A number of acquisitions last year disclosed no sale price. In the Indianapolis area, those deals ranged from MacAllister Machinery’s purchase of a Caterpillar dealership in Michigan to Herff Jones’ acquisition of a Memphis, Tenn.-headquartered maker of cheerleading uniforms.
Polymer Technology Systems said in 2007 that it would make a $3 million investment at its operation on Zionsville Road and create 110 jobs.
The OK for a new blood glucose monitor comes more than two years after FDA officials declined to approve a previous version of the Nano, which in rare cases generated inflated blood sugar readings because it did not distinguish properly between the sugars glucose and maltose.
A new report by BioCrossroads says 53 percent of the 20,000 jobs in Indiana’s medical-device sector require no more than a high school education.
New York-based Epstein Becker Green already has clients here, including Biomet and Roche Diagnostics.
After spending most of 2011 as a Wall Street darling, the year ended ugly for Endocyte Inc. But CEO Ron Ellis thinks the West Lafayette-based drug developer is in better position than ever.
It’s hard to believe now, but as recently as two years ago, Indianapolis was close to losing its 15th-largest employer. Roche Diagnostics Corp. was looking seriously at moving its 2,900-employee North American headquarters out of Indianapolis.
Kexue Huang was sentenced after pleading guilty in October to sending Dow AgroSciences trade secrets to China and Germany.
Federal prosecutors are recommending that Kexue Huang be sentenced to 87 months in prison for sending trade secrets worth millions to China and Germany.
Regulators allege CEO Patrick G. Rooney diverted millions of dollars from a hedge fund into the struggling Fishers company without investors’ knowledge.
The office, at NASA Ames Research Center, in Mountain View, Calif., aims to commercialize Purdue-developed technology through partnerships with private industry.
For Indiana’s life sciences sector, the change both raises hopes and creates challenges for continued growth.
Endocyte employs 12 people in Indianapolis and plans to add three or four more commercial executives there over the next year and a half as it anticipates approval of its ovarian cancer medication in Europe.